Stockscreener 앱 받기
37.48
0.79%
-0.30
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Rigel Pharmaceuticals (RIGL) Valuation After New REZLIDHIA Trial And 2026 Revenue Guidance - simplywall.st
Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025 - Insider Monkey
Is Rigel Pharmaceuticals (RIGL) 2026 Revenue Guidance Reframing Its Commercial-Led Investment Narrative? - Yahoo Finance
Precision Trading with Rigel Pharmaceuticals Inc. (RIGL) Risk Zones - Stock Traders Daily
New leukemia drug combo enters trial for patients with hard-to-treat AML - Stock Titan
HC Wainwright Has Negative Forecast for RIGL FY2026 Earnings - MarketBeat
Rigel Pharmaceuticals price target raised to $71 from $69 at Citi - TipRanks
10 Best Performing Affordable Stocks Under $40 - Insider Monkey
A Look At Rigel Pharmaceuticals (RIGL) Valuation After Issuing 2026 Revenue Guidance - Yahoo Finance
Equities Analysts Issue Forecasts for RIGL FY2025 Earnings - MarketBeat
Will Rigel Pharmaceuticals Inc stock outperform tech sector in 2025Gap Down & Low Drawdown Trading Strategies - Bộ Nội Vụ
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rigel Pharmaceuticals (RIGL) Is Down 7.7% After Issuing Detailed 2026 Revenue Mix Guidance – Has The Bull Case Changed? - simplywall.st
Rigel Announces Strong Preliminary 2025 Results and Outlook - TipRanks
Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $291.58M - TipRanks
Rigel Pharmaceuticals (RIGL) Reports Impressive Financial Results - GuruFocus
Rigel (RIGL) Projects Strong Revenue Growth for 2025 - GuruFocus
Rigel Provides Business Update and 2026 Outlook - marketscreener.com
Rigel Provides Business Update and 2026 Outlook – Company Announcement - Financial Times
Why Rigel Pharmaceuticals Inc. stock is popular among millennials2025 Technical Overview & Short-Term Trading Alerts - ulpravda.ru
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates - sharewise.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading Down 5.3%Here's What Happened - MarketBeat
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NA - GuruFocus
Rigel Pharmaceuticals, Inc. announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - StreetInsider
Earnings Risk: Will Rigel Pharmaceuticals Inc. (RI2) stock gain from green policies2025 Price Momentum & Expert Approved Momentum Ideas - Улправда
Is Rigel Pharmaceuticals Inc. stock a buy in volatile markets2025 Major Catalysts & Long-Term Growth Stock Strategies - Улправда
Is Rigel Pharmaceuticals Inc. stock supported by strong cash flows2025 Support & Resistance & Real-Time Sentiment Analysis - ulpravda.ru
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt? - simplywall.st
Rigel Pharmaceuticals, Inc. (RIGL) Investor Outlook: Strong Revenue Growth and Promising Upside - DirectorsTalk Interviews
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio - The Manila Times
SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030Rigel Pharmaceuticals Lea - PharmiWeb.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading 8.4% HigherStill a Buy? - MarketBeat
About Us - FinancialContent
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference - StreetInsider
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Rating Upgraded by Zacks Research - MarketBeat
Best Momentum Stocks to Buy for January 6th - Yahoo Finance
Why Analysts Say The Rigel Pharmaceuticals (RIGL) Story Is Shifting After Q3 And 2025 Guidance - Yahoo Finance
Technical Reactions to RIGL Trends in Macro Strategies - Stock Traders Daily
Is Rigel Pharmaceuticals Inc. stock near bottom after decline2025 Year in Review & Growth Focused Entry Reports - moha.gov.vn
What analysts say about Rigel Pharmaceuticals Inc RI2 stockLow Beta Stocks & Low Risk Investment Growth - earlytimes.in
Jhandewalas Foods Limited Earnings Review What Investors Need to KnowHigh Dividend Yield Stocks & See Risk Factors Before Making Any Move - earlytimes.in
Rigel Pharma: Formulating A Game Plan For 2026 - Seeking Alpha
Rigel Pharmaceuticals, Inc. $RIGL Shares Sold by Voya Investment Management LLC - MarketBeat
Pacer Advisors Inc. Buys New Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
Range Financial Group LLC Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals (RIGL) CFO reports multiple option exercises and share ownership - Stock Titan
Rigel Pharmaceuticals: Formulating A Game Plan For 2026 (NASDAQ:RIGL) - Seeking Alpha
Rigel enrols first subject in Phase I sickle cell disease therapy trial - MSN
With EPS Growth And More, Rigel Pharmaceuticals (NASDAQ:RIGL) Makes An Interesting Case - Yahoo Finance
Inspire Investing LLC Makes New $859,000 Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Momentum Shift: Will Rigel Pharmaceuticals Inc RI2 stock beat Nasdaq index returnsInsider Selling & Free Growth Oriented Trading Recommendations - moha.gov.vn
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 23% Below Their Intrinsic Value Estimate - 富途牛牛
Assenagon Asset Management S.A. Decreases Holdings in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
(RIGL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
4.73%
0.92%
자본화:
|
볼륨(24시간):